Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Bast, RC, Pusztai, L, Kerns, BJ, MacDonald, JA, Jordan, P, Daly, L, Boyer, CM, Mendelsohn, J, and Berchuck, A. "Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues." Hybridoma 17, no. 4 (August 1998): 313-321.

Full Text

Maxwell, GL, Risinger, JI, Tong, B, Shaw, H, Barrett, JC, Berchuck, A, and Futreal, PA. "Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers." Gynecol Oncol 70, no. 1 (July 1998): 13-16.

Full Text

Lancaster, JM, Berchuck, A, Carney, ME, Wiseman, R, and Taylor, JA. "Progesterone receptor gene polymorphism and risk for breast and ovarian cancer." Br J Cancer 78, no. 2 (July 1998): 277-. (Letter)

Scholars@Duke

Boente, MP, Berchuck, A, Whitaker, RS, Kalén, A, Xu, FJ, Clarke-Pearson, DL, Bell, RM, and Bast, RC. "Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines." Gynecol Oncol 70, no. 1 (July 1998): 49-55.

Full Text

Maxwell, GL, Risinger, JI, Gumbs, C, Shaw, H, Bentley, RC, Barrett, JC, Berchuck, A, and Futreal, PA. "Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias." Cancer Res 58, no. 12 (June 15, 1998): 2500-2503.

Scholars@Duke

Arrigo, L, Pierre, Y, Berchuck, A, Morris, DL, Yeung, KK, and Very, DL. "The Bayer Immuno 1 (TM) CA 125 II (TM) assay: An automated assay for the clinical management of ovarian cancer patients." CLINICAL CHEMISTRY 44 (June 1998): A44-A44.

Scholars@Duke

Berchuck, A, Carney, M, Lancaster, JM, Marks, J, and Futreal, AP. "Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2." Clin Obstet Gynecol 41, no. 1 (March 1998): 157-166. (Review)

Scholars@Duke

Berchuck, A. "Molecular genetics of hereditary ovarian cancer - The Boyd article reviewed." ONCOLOGY-NEW YORK 12, no. 3 (March 1998): 410-+.

Scholars@Duke

Young, SR, Liu, WH, and Berchuck, A. "Dual-color FISH studies of HER2/neu and centromere 17 in archived paraffin-embedded ovarian cancer samples." CYTOGENETICS AND CELL GENETICS 82, no. 1-2 (1998): 136-137.

Scholars@Duke

Layfield, LJ, Saria, EA, Berchuck, A, Dodge, RK, Thompson, JK, Conlon, DH, and Kerns, BJ. "Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis." J Surg Oncol 66, no. 4 (December 1997): 230-236.

Scholars@Duke

Pages